A Phase 3 interventional study of IMVT-1402 and IMVT-1402 in Generalized Myasthenia Gravis, sponsored by Immunovant Sciences GmbH. Recruiting at 88 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Immunovant Sciences GmbH · Phase 3, Interventional, and Treatment
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
324 studies on the registry are indexed under Myasthenia Gravis; 146 are open to participants now.
This study's planned enrollment of 231 is above the median of 44 across 212 interventional studies indexed under Myasthenia Gravis.
Browse Myasthenia Gravis studies →Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Additional inclusion criteria are defined in the protocol.
Exclusion Criteria:
Additional exclusion criteria are defined in the protocol.
Drug: IMVT-1402
Drug: IMVT-1402
Drug: Placebo · Drug: IMVT-1402
• Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)
* Dose 2 SC QW for 12 weeks (Period 1) * Dose 2 SC QW for 14 weeks (Period 2) * Dose 2 SC QW for 52 weeks (Period 3)
• Placebo SC QW for 12 weeks (Period 1)
* Dose 1 SC QW for 14 weeks (Period 2) * Dose 1 SC QW for 52 weeks (Period 3)
Change from Baseline in MG-ADL Score for Antibody-positive Participants
Time frame: Baseline to Week 12
Change from Baseline in Quantitative Myasthenia Gravis (QMG) Score for Antibody-positive Participants
Time frame: Baseline to Week 12
Percentage of Antibody-positive Participants Achieving MG-ADL Score of 0 or 1
Time frame: Week 12
Percentage of Antibody-positive Participants with ≥50% Improvement in MG-ADL Score
Time frame: Baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunovant Sciences GmbH